Anticancer effects and potential mechanisms of ginsenoside Rh2 in various cancer types (Review)
- Authors:
- Haibo Zhang
- Song Park
- Hai Huang
- Eungyung Kim
- Junkoo Yi
- Seong-Kyoon Choi
- Zaeyoung Ryoo
- Myoungok Kim
-
Affiliations: Department of Animal Science and Biotechnology, Institute for Translational Research in Dentistry, Kyungpook National University, Bukgu, Daegu 41566, Republic of Korea, Core Protein Resources Center, Daegu Gyeongbuk Institute of Science and Technology, Daegu 41566, Republic of Korea, Gyeongsangbukdo Livestock Institute Research, Yeongju, Gyeongsangbukdo 36052, Republic of Korea, School of Life Sciences, Brain Korea 21 Fostering Outstanding Universities for Research Kyungpook National University Creative BioResearch, Kyungpook National University, Daegu 41566, Republic of Korea - Published online on: February 19, 2021 https://doi.org/10.3892/or.2021.7984
- Article Number: 33
This article is mentioned in:
Abstract
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
Shahab D, Gabriel E, Attwood K, Ma WW, Francescutti V, Nurkin S and Boland PM: Adjuvant chemotherapy is associated with improved overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation. Clin Colorectal Cancer. 16:300–307. 2017. View Article : Google Scholar : PubMed/NCBI | |
Fujita K, Taneishi K, Inamoto T, Ishizuya Y, Takada S, Tsujihata M, Tanigawa G, Minato N, Nakazawa S, Takada T, et al: Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: A propensity score-matched analysis. BMC Urol. 17:1102017. View Article : Google Scholar : PubMed/NCBI | |
Lu JM, Yao Q and Chen C: Ginseng compounds: An update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol. 7:293–302. 2009. View Article : Google Scholar : PubMed/NCBI | |
Hou J, Xue J, Lee M, Liu L, Zhang D, Sun M, Zheng Y and Sung C: Ginsenoside Rh2 improves learning and memory in mice. J Med Food. 16:772–776. 2013. View Article : Google Scholar : PubMed/NCBI | |
Qian Y, Huang R, Li S, Xie R, Qian B, Zhang Z, Li L, Wang B, Tian C, Yang J, et al: Ginsenoside Rh2 reverses cyclophosphamide-induced immune deficiency by regulating fatty acid metabolism. J Leukoc Biol. 106:1089–1100. 2019. View Article : Google Scholar : PubMed/NCBI | |
Choi WY, Lim HW and Lim CJ: Anti-inflammatory, antioxidative and matrix metalloproteinase inhibitory properties of 20(R)-ginsenoside Rh2 in cultured macrophages and keratinocytes. J Pharm Pharmacol. 65:310–316. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang XP, Li KR, Yu Q, Yao MD, Ge HM, Li XM, Jiang Q, Yao J and Cao C: Ginsenoside Rh2 inhibits vascular endothelial growth factor-induced corneal neovascularization. FASEB J. 32:3782–3791. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhou J, Gao Y, Yi X and Ding Y: Ginsenoside Rh2 suppresses neovascularization in xenograft psoriasis model. Cell Physiol Biochem. 36:980–987. 2015. View Article : Google Scholar : PubMed/NCBI | |
Choi K, Kim M, Ryu J and Choi C: Ginsenosides compound K and Rh(2) inhibit tumor necrosis factor-alpha-induced activation of the NF-kappaB and JNK pathways in human astroglial cells. Neurosci Lett. 421:37–41. 2007. View Article : Google Scholar : PubMed/NCBI | |
Bae EA, Kim EJ, Park JS, Kim HS, Ryu JH and Kim DH: Ginsenosides Rg3 and Rh2 inhibit the activation of AP-1 and protein kinase A pathway in lipopolysaccharide/interferon-gamma-stimulated BV-2 microglial cells. Planta Med. 72:627–633. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Wang H, Liu Y, Li C, Qi P and Bao J: Antihyperglycemic effect of ginsenoside Rh2 by inducing islet β-cell regeneration in mice. Horm Metab Res. 44:33–40. 2012. View Article : Google Scholar : PubMed/NCBI | |
Huang YQ, Huang HX, Han ZD, Li W, Mai ZP and Yuan RQ: Ginsenoside Rh2 Inhibits Angiogenesis in Prostate Cancer by Targeting CNNM1. J Nanosci Nanotechnol. 19:1942–1950. 2019. View Article : Google Scholar : PubMed/NCBI | |
Tong-Lin Wu T, Tong YC, Chen IH, Niu HS, Li Y and Cheng JT: Induction of apoptosis in prostate cancer by ginsenoside Rh2. Oncotarget. 9:11109–11118. 2018. View Article : Google Scholar : PubMed/NCBI | |
Shi X, Yang J and Wei G: Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through the Akt/GSK3β signaling pathway in human cervical cancer cells. Mol Med Rep. 17:4811–4816. 2018.PubMed/NCBI | |
Wang YS, Lin Y, Li H, Li Y, Song Z and Jin YH: The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity. Sci Rep. 7:124082017. View Article : Google Scholar : PubMed/NCBI | |
Yang J, Yuan D, Xing T, Su H, Zhang S, Wen J, Bai Q and Dang D: Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase. J Ginseng Res. 40:400–408. 2016. View Article : Google Scholar : PubMed/NCBI | |
Han S, Jeong AJ, Yang H, Bin Kang K, Lee H, Yi EH, Kim BH, Cho CH, Chung JW, Sung SH and Ye SK: Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells. J Ethnopharmacol. 194:83–90. 2016. View Article : Google Scholar : PubMed/NCBI | |
Kim MJ, Yun H, Kim DH, Kang I, Choe W, Kim SS and Ha J: AMP-activated protein kinase determines apoptotic sensitivity of cancer cells to ginsenoside-Rh2. J Ginseng Res. 38:16–21. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tang XP, Tang GD, Fang CY, Liang ZH and Zhang LY: Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells. World J Gastroenterol. 19:1582–1592. 2013. View Article : Google Scholar : PubMed/NCBI | |
Li KF, Kang CM, Yin XF, Li HX, Chen ZY, Li Y, Zhang Q and Qiu YR: Ginsenoside Rh2 inhibits human A172 glioma cell proliferation and induces cell cycle arrest status via modulating Akt signaling pathway. Mol Med Rep. 17:3062–3068. 2018.PubMed/NCBI | |
Ge G, Yan Y and Cai H: Ginsenoside Rh2 inhibited proliferation by inducing ROS mediated ER stress dependent apoptosis in lung cancer cells. Biol Pharma Bull. 40:2117–2124. 2017. View Article : Google Scholar | |
Li H, Huang N, Zhu W, Wu J, Yang X, Teng W, Tian J, Fang Z, Luo Y, Chen M and Li Y: Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2. BMC Cancer. 18:5792018. View Article : Google Scholar : PubMed/NCBI | |
An IS, An S, Kwon KJ, Kim YJ and Bae S: Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells. Oncol Rep. 29:523–528. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Zhang Y, Song W, Zhang Y, Dong X and Tan M: Ginsenoside Rh2 inhibits migration of lung cancer cells under hypoxia via mir-491. Anticancer Agents Med Chem. 19:1633–1641. 2019. View Article : Google Scholar : PubMed/NCBI | |
Cheng CC, Yang SM, Huang CY, Chen JC, Chang WM and Hsu SL: Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Cancer Chemother Pharmacol. 55:531–540. 2005. View Article : Google Scholar : PubMed/NCBI | |
Chen W, Chu S, Li H and Qiu Y: MicroRNA-146a-5p enhances ginsenoside Rh2-induced anti-proliferation and the apoptosis of the human liver cancer cell line HepG2. Oncol Lett. 16:5367–5374. 2018.PubMed/NCBI | |
Chen W and Qiu Y: Ginsenoside Rh2 Targets EGFR by up-regulation of miR-491 to enhance anti-tumor activity in hepatitis B virus-related hepatocellular carcinoma. Cell Biochem Biophys. 72:325–331. 2015. View Article : Google Scholar : PubMed/NCBI | |
Qian J, Li J, Jia JG, Jin X, Yu DJ, Guo CX, Xie B and Qian LY: Ginsenoside-Rh2 inhibits proliferation and induces apoptosis of human gastric cancer SGC-7901 side population cells. Asian Pac J Cancer Prev. 17:1817–1821. 2016. View Article : Google Scholar : PubMed/NCBI | |
Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS and Du W: Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett. 301:185–192. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhu C, Liu F, Qian W, Zhang T and Li F: Combined effect of sodium selenite and Ginsenoside Rh2 on hct116 human colorectal carcinoma cells. Arch Iran Med. 19:23–29. 2016.PubMed/NCBI | |
Oh M, Choi YH, Choi S, Chung H, Kim K, Kim SI, Kim DK and Kim ND: Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol. 14:869–875. 1999.PubMed/NCBI | |
Lee H, Lee S, Jeong D and Kim SJ: Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells. J Ginseng Res. 42:455–462. 2018. View Article : Google Scholar : PubMed/NCBI | |
Choi S, Kim TW and Singh SV: Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res. 26:2280–2288. 2009. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Shimizu K, Yu H, Zhang C, Jin F and Kondo R: Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. Fitoterapia. 81:902–905. 2010. View Article : Google Scholar : PubMed/NCBI | |
Zhang Q, Hong B, Wu S and Niu T: Inhibition of prostatic cancer growth by ginsenoside Rh2. Tumour Biol. 36:2377–2381. 2015. View Article : Google Scholar : PubMed/NCBI | |
Gao Q and Zheng J: Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A. Cell Prolif. 51:e124382018. View Article : Google Scholar : PubMed/NCBI | |
Xia T, Wang YN, Zhou CX, Wu LM, Liu Y, Zeng QH, Zhang XL, Yao JH, Wang M and Fang JP: Ginsenoside Rh2 and Rg3 inhibit cell proliferation and induce apoptosis by increasing mitochondrial reactive oxygen species in human leukemia Jurkat cells. Mol Med Rep. 15:3591–3598. 2017. View Article : Google Scholar : PubMed/NCBI | |
Xia T, Wang J, Wang Y, Wang Y, Cai J, Wang M, Chen Q, Song J, Yu Z, Huang W and Fang J: Inhibition of autophagy potentiates anticancer property of 20(S)-ginsenoside Rh2 by promoting mitochondria-dependent apoptosis in human acute lymphoblastic leukaemia cells. Oncotarget. 7:27336–27349. 2016. View Article : Google Scholar : PubMed/NCBI | |
Huang J, Peng K, Wang L, Wen B, Zhou L, Luo T, Su M, Li J and Luo Z: Ginsenoside Rh2 inhibits proliferation and induces apoptosis in human leukemia cells via TNF-alpha signaling pathway. Acta Biochim Biophys Sin (Shanghai). 48:750–755. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Liu ZH, Xia J, Li XP, Li KQ, Xiong W, Li J and Chen DL: 20(S)-ginsenoside Rh2 inhibits the proliferation and induces the apoptosis of KG-1a cells through the Wnt/β-catenin signaling pathway. Oncol Rep. 36:137–146. 2016. View Article : Google Scholar : PubMed/NCBI | |
Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, Kudoh K, Nagata I and Shinomiya N: Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res. 89:733–740. 1998. View Article : Google Scholar : PubMed/NCBI | |
Tode T, Kikuchi Y, Kita T, Hirata J, Imaizumi E and Nagata I: Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice. J Cancer Res Clin Oncol. 120:24–26. 1993. View Article : Google Scholar : PubMed/NCBI | |
Li N, Lin Z, Chen W, Zheng Y, Ming Y, Zheng Z, Huang W, Chen L, Xiao J and Lin H: Corilagin from longan seed: Identification, quantification, and synergistic cytotoxicity on SKOv3ip and hey cells with ginsenoside Rh2 and 5-fluorouracil. Food Chem Toxicol. 119:133–140. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kim JH and Choi JS: Effect of ginsenoside Rh-2 via activation of caspase-3 and Bcl-2-insensitive pathway in ovarian cancer cells. Physiol Res. 65:1031–1037. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhang C, Yu H and Hou J: Effects of 20 (S)-ginsenoside Rh2 and 20 (R)-ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cells. Zhongguo Zhong Yao Za Zhi. 36:1670–1674. 2011.(In Chinese). PubMed/NCBI | |
Dong H, Bai LP, Wong VK, Zhou H, Wang JR, Liu Y, Jiang ZH and Liu L: The in vitro structure-related anti-cancer activity of ginsenosides and their derivatives. Molecules. 16:10619–10630. 2011. View Article : Google Scholar : PubMed/NCBI | |
Harashima H, Dissmeyer N and Schnittger A: Cell cycle control across the eukaryotic kingdom. Trends Cell Biol. 23:345–356. 2013. View Article : Google Scholar : PubMed/NCBI | |
Roskoski R Jr: Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol Res. 139:471–488. 2019. View Article : Google Scholar : PubMed/NCBI | |
Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Sun Y, Yue L, Li S, Qi X, Zhao H, Yang Y, Zhang C and Yu H: JNK pathway and relative transcriptional factor were involved in ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Genet Mol Res. 15:2016. View Article : Google Scholar | |
Chung KS, Cho SH, Shin JS, Kim DH, Choi JH, Choi SY, Rhee YK, Hong HD and Lee KT: Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression. Carcinogenesis. 34:331–340. 2013. View Article : Google Scholar : PubMed/NCBI | |
Fuchs Y and Steller H: Programmed cell death in animal development and disease. Cell. 147:742–758. 2011. View Article : Google Scholar : PubMed/NCBI | |
Plati J, Bucur O and Khosravi-Far R: Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J Cell Biochem. 104:1124–1149. 2008. View Article : Google Scholar : PubMed/NCBI | |
Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI | |
Guo XX, Li Y, Sun C, Jiang D, Lin YJ, Jin FX, Lee SK and Jin YH: p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells. Protein Cell. 5:224–234. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang X and Wang Y: Ginsenoside Rh2 mitigates pediatric leukemia through suppression of Bcl-2 in leukemia cells. Cell Physiol Biochem. 37:641–650. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li Q, Li Y, Wang X, Fang X, He K, Guo X, Zhan Z, Sun C and Jin YH: Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release. Mol Carcinog. 50:760–769. 2011. View Article : Google Scholar : PubMed/NCBI | |
Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI | |
Manning BD and Cantley LC: AKT/PKB signaling: Navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI | |
Liu ZH, Li J, Xia J, Jiang R, Zuo GW, Li XP, Chen Y, Xiong W and Chen DL: Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells. Chem Biol Interact. 242:227–234. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Yi J, Kim E, Choo Y, Hai H, Kim K, Kim EK, Ryoo Z and Kim M: 20(S)-Ginsenoside Rh2 suppresses oral cancer cell growth by inhibiting the Src-Raf-ERK signaling pathway. Anticancer Res. 41:227–235. 2021. View Article : Google Scholar : PubMed/NCBI | |
Wu N, Wu GC, Hu R, Li M and Feng H: Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin. 32:345–353. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ishay-Ronen D, Diepenbruck M, Kalathur RKR, Sugiyama N, Tiede S, Ivanek R, Bantug G, Morini MF, Wang J, Hess C and Christofori G: Gain fat-lose metastasis: Converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell. 35:17–32.e6. 2019. View Article : Google Scholar : PubMed/NCBI | |
Kim JH, Kim M, Yun SM, Lee S, No JH, Suh DH, Kim K and Kim YB: Ginsenoside Rh2 induces apoptosis and inhibits epithelial-mesenchymal transition in HEC1A and Ishikawa endometrial cancer cells. Biomed Pharmacother. 96:871–876. 2017. View Article : Google Scholar : PubMed/NCBI | |
Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI | |
Zhang BP, Li B, Cheng JY, Cao R, Gao ST, Huang CJ, Li RP, Ning J, Liu B and Li ZG: Anti-cancer Effect of 20(S)-Ginsenoside-Rh2 on oral squamous cell carcinoma cells via the decrease in ROS and downregulation of MMP-2 and VEGF. Biomed Environ Sci. 33:713–717. 2020.PubMed/NCBI | |
Riabov V, Gudima A, Wang N, Mickley A, Orekhov A and Kzhyshkowska J: Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 5:752014. View Article : Google Scholar : PubMed/NCBI | |
Goumans MJ, Liu Z and ten Dijke P: TGF-beta signaling in vascular biology and dysfunction. Cell Res. 19:116–127. 2009. View Article : Google Scholar : PubMed/NCBI | |
Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI | |
Wang Q, Wu MQ, Zhao LH, Yang HK and Lv XH: Effect of ginsenoside Rh2 on transplanted-tumor and expression of JAM in mice. Zhongguo Zhong Yao Za Zhi. 33:2116–2119. 2008.(In Chinese). PubMed/NCBI | |
Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature. 451:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ryan KM: p53 and autophagy in cancer: Guardian of the genome meets guardian of the proteome. Eur J Cancer. 47:44–50. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhuang J, Yin J, Xu C, Mu Y and Lv S: 20(S)-Ginsenoside Rh2 Induce the Apoptosis and Autophagy in U937 and K562 Cells. Nutrients. 10:3282018. View Article : Google Scholar | |
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016. View Article : Google Scholar : PubMed/NCBI | |
Liu S, Chen M, Li P, Wu Y, Chang C, Qiu Y, Cao L, Liu Z and Jia C: Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. Cell Physiol Biochem. 36:499–508. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li M, Zhang D, Cheng J, Liang J and Yu F: Ginsenoside Rh2 inhibits proliferation but promotes apoptosis and autophagy by down-regulating microRNA-638 in human retinoblastoma cells. Exp Mol Pathol. 108:17–23. 2019. View Article : Google Scholar : PubMed/NCBI | |
Ma J, Gao G, Lu H, Fang D, Li L, Wei G, Chen A, Yang Y, Zhang H and Huo J: Reversal effect of ginsenoside Rh2 on oxaliplatin-resistant colon cancer cells and its mechanism. Exp Ther Med. 18:630–636. 2019.PubMed/NCBI | |
Zhou B, Xiao X, Xu L, Zhu L, Tan L, Tang H, Zhang Y, Xie Q and Yao S: A dynamic study on reversal of multidrug resistance by ginsenoside Rh(2) in adriamycin-resistant human breast cancer MCF-7 cells. Talanta. 88:345–351. 2012. View Article : Google Scholar : PubMed/NCBI | |
Liu GW, Liu YH, Jiang GS and Ren WD: The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell. 31:189–198. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lv DL, Chen L, Ding W, Zhang W, Wang HL, Wang S and Liu WB: Ginsenoside G-Rh2 synergizes with SMI-4a in anti-melanoma activity through autophagic cell death. Chin Med. 13:112018. View Article : Google Scholar : PubMed/NCBI | |
Wang M, Yan SJ, Zhang HT, Li N, Liu T, Zhang YL, Li XX, Ma Q, Qiu XC, Fan QY and Ma BA: Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model. Oncol Lett. 13:681–685. 2017. View Article : Google Scholar : PubMed/NCBI | |
Xia T, Zhang B, Li Y, Fang B, Zhu XX, Xu BC, Zhang J, Wang M and Fang JP: New insight into 20(S)-ginsenoside Rh2 against T-cell acute lymphoblastic leukemia associated with the gut microbiota and the immune system. Eur J Med Chem. 203:1125392020. View Article : Google Scholar : PubMed/NCBI | |
Li Q, Li B, Dong C, Wang Y and Li Q: 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription. Eur J Pharmacol. 815:173–180. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shi Q, Shi X, Zuo G, Xiong W, Li H, Guo P, Wang F, Chen Y, Li J and Chen DL: Anticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: Activating GSK-3β and degrading β-catenin. Oncol Rep. 36:2059–2070. 2016. View Article : Google Scholar : PubMed/NCBI | |
Qian T, Cai Z, Wong RN and Jiang ZH: Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Commun Mass Spectrom. 19:3549–3554. 2005. View Article : Google Scholar : PubMed/NCBI | |
Qi Z, Chen L, Li Z, Shao Z, Qi Y, Gao K, Liu S, Sun Y, Li P and Liu J: Immunomodulatory effects of (24R)-Pseudo-Ginsenoside HQ and (24S)-Pseudo-Ginsenoside HQ on cyclophosphamide-induced immunosuppression and their anti-tumor effects study. Int J Mol Sci. 20:8362019. View Article : Google Scholar | |
Gu Y, Wang GJ, Sun JG, Jia YW, Wang W, Xu MJ, Lv T, Zheng YT and Sai Y: Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. Food Chem Toxicol. 47:2257–2268. 2009. View Article : Google Scholar : PubMed/NCBI | |
Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T and Liu Y: EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol. 35:5593–5598. 2014. View Article : Google Scholar : PubMed/NCBI | |
Xia T, Wang JC, Xu W, Xu LH, Lao CH, Ye QX and Fang JP: 20S-Ginsenoside Rh2 induces apoptosis in human Leukaemia Reh cells through mitochondrial signaling pathways. Biol Pharm Bull. 37:248–254. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kim YS and Jin SH: Ginsenoside Rh2 induces apoptosis via activation of caspase-1 and −3 and up-regulation of Bax in human neuroblastoma. Arch Pharm Res. 27:834–839. 2004. View Article : Google Scholar : PubMed/NCBI | |
Shi Q, Li J, Feng Z, Zhao L, Luo L, You Z, Li D, Xia J, Zuo G and Chen D: Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: Recruiting histone deacetylase and inhibiting activator protein 1 transcription factors. Mol Med Rep. 10:1779–1785. 2014. View Article : Google Scholar : PubMed/NCBI | |
Guan N, Huo X, Zhang Z, Zhang S, Luo J and Guo W: Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13. Tumour Biol. 36:6789–6795. 2015. View Article : Google Scholar : PubMed/NCBI | |
Xia T, Zhang J, Zhou C, Li Y, Duan W, Zhang B, Wang M and Fang J: 20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway. J Ginseng Res. 44:725–737. 2020. View Article : Google Scholar : PubMed/NCBI | |
Li S, Guo W, Gao Y and Liu Y: Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor. Tumour Biol. 36:2607–2612. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li C, Gao H, Feng X, Bi C, Zhang J and Yin J: Ginsenoside Rh2 impedes proliferation and migration and induces apoptosis by regulating NF-κB, MAPK, and PI3K/Akt/mTOR signaling pathways in osteosarcoma cells. J Biochem Mol Toxicol. 34:e225972020. View Article : Google Scholar : PubMed/NCBI | |
Yang D, Li X and Zhang X: Ginsenoside Rh2 induces DNA damage and autophagy in vestibular schwannoma is dependent of LAMP2 transcriptional suppression. Biochem Biophys Res Commun. 522:300–307. 2020. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Zhang Y, Song W, Zhang Y, Dong X and Tan M: Ginsenoside Rh2 improves the cisplatin anti-tumor effect in lung adenocarcinoma A549 cells via superoxide and PD-L1. Anticancer Agents Med Chem. 20:495–503. 2020. View Article : Google Scholar : PubMed/NCBI |